A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
Metastatic breast cancer; alternative treatment schedules; maintenance chemotherapy
Abstract :
[en] Background: The phase II SNAP trial was designed to evaluate the efficacy of alternative chemotherapy schedules for prolonged administration in HER2-negative metastatic breast cancer (MBC), after a short induction at conventional doses. Methods: Between April 2013 and August 2015, 258 women untreated with chemotherapy for MBC were randomly assigned to receive three different maintenance chemotherapy schedules after three cycles of identical induction chemotherapy: Arm A, nab-Paclitaxel 150 mg/m2 days 1,15 Q28; Arm B, nab-Paclitaxel 100 mg/m2 days 1,8,15 Q28; Arm C, nab-Paclitaxel 75 mg/m2 days 1,8,15,22 Q28. Induction was three cycles nab-Paclitaxel 150/125 mg/m2, days 1,8,15 Q28. The primary objective was to evaluate the efficacy of each maintenance schedule, in terms of progression-free survival (PFS), as compared to the historical reference of 7-month median PFS reported by previous studies with first-line docetaxel. One-sample, one-sided log-rank tests were utilized. Quality-of-life evaluation was performed, global indicator for physical well-being was defined as the primary endpoint; completion rates of quality-of-life forms were >90%. Results: 255 patients were evaluable for the primary endpoint. After 18.2 months median follow-up, 182 PFS events were observed. Median PFS was 7.9 months (90%CI 6.8-8.4) in Arm A, 9.0 months (90%CI 8.1-10.9) in Arm B and 8.5 months (90%CI 6.7-9.5) in Arm C. PFS in Arm B was significantly longer than the historical reference of first-line docetaxel (P=0.03). Grade>/=2 sensory neuropathy was reported in 37.9%, 36.1% and 31.2% of patients in Arm A, Arm B and Arm C, respectively (Grade>/=3 in 9.1%, 5.6% and 6.6% of patients, respectively). Noteworthy, the quality-of-life scores for sensory neuropathy did not worsen with prolonged nab-Paclitaxel administration in any of the maintenance arms. Conclusion: The SNAP trial demonstrated that alternative nab-Paclitaxel maintenance schedules with reduced dosages after a short induction at conventional doses are feasible and active in the first-line treatment of MBC. Registration: ClinicalTrials.gov NCT01746225.
Disciplines :
Oncology
Author, co-author :
Gennari, A.
Sun, Z.
Hasler-Strub, U.
Colleoni, Marco
Kennedy, M. J.
Von Moos, R.
Cortes, J.
Vidal, M. J.
Hennessy, B.
Walshe, J.
Amillano Parraga, K.
Ribi, Karin
Bernhard, J.
Morales, S. Murillo
Pagani, O.
Barbeaux, A.
Borstnar, S.
Rabaglio-Poretti, M.
Maibach, R.
Regan, M. M.
Jerusalem, Guy ; Université de Liège - ULiège > Département des sciences cliniques > Oncologie
A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28: 16-33.
Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110: 973-979.
Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104: 1742-1750.
Bonotto M, Gerratana L, Di Maio M, et al. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis. Breast 2017; 31: 114-120.
Coates AS, Byrne M, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer: Intermittent versus continuous chemotherapy for breast cancer. N Engl J Med 1987; 317: 1490-1495.
Harris AL, Cantwell BM, Carmichael J, et al. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 1990; 335: 186-190.
Muss HB, Case LD, Richards F, II, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer: the Piedmont Oncology Association. N Engl J Med 1991; 325: 1342-1348.
Ejlertsen B, Pfeiffer P, Pedersen D, et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 1993; 29A: 527-531.
Gregory RK, Powles TJ, Chang JC, et al. A randomized trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 1997; 33: 2194-2197.
Falkson G, Gelman RS, Pandya KJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with breast cancer in complete remission following induction treatment. J Clin Oncol 1998; 16: 1669-1676.
French Epirubicin Study Group. Epirubicin based chemotherapy in metastatic breast cancer patients: Role of dose intensity and duration of treatment. J Clin Oncol 2000; 18: 3115-3124.
Nooij MA, de Haes JCJM, Beex LVAM, et al. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: Clinical outcomes and oncologists' preferences. Eur J Cancer 2003; 39: 614-621.
Gennari A, Amadori D, De Lena M, et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 2006; 24: 3912-3917.
Mayordomo J, Baena JM, Cirera P, et al. Final results of a randomised trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer. J Clin Oncol 2001; 27: 41s (abstr 1001).
Alba E, Ruiz-Borrego M, Margelí M, et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 2010; 122: 169-176.
Park YH, Jung KH, Im SA, et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol 2013; 31: 1732-1739.
Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011; 20: 2144-2149.
Partridge AH, Smith IE, Rumble RB. Chemo-and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 2015; 11: 42-43.
Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-Paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27: 3611-3619.
Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-7803.
Park YH, Jung KH, Im SA, et al. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). Breast Cancer Res Treat 2015; 152: 77-85.
Ghislain I, Zikos E, Coens C, et al. Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. Lancet Oncol 2016; 17: e294-e304.